GLPG3970 SIK2/3 Inhibitor: Antidepressant Effects in Preclinical Models

GLPG3970 Demonstrates Antidepressant-Like Effects in Mouse Models

GLPG3970, a selective inhibitor of salt-inducible kinases 2 and 3 (SIK2/3), has been shown to produce antidepressant-like effects in two validated mouse models of chronic stress: chronic social defeat stress (CSDS) and chronic unpredictable mild stress (CUMS). The study, published on October 1, 2026 (OpenAlex W7215059801), provides preclinical evidence that repeated administration of GLPG3970 reduces depressive-like behaviors in male C57BL/6J mice. These findings are significant as they offer a mechanistically distinct approach to antidepressant development, targeting pathways not addressed by conventional therapies.

Mechanism: SIK2-CRTC1-CREB-BDNF Pathway and Neurogenesis

The antidepressant-like effects of GLPG3970 are mediated through the hippocampal SIK2-CRTC1-CREB-BDNF signaling pathway. This pathway is central to neuroplasticity and has been implicated in the action of both traditional and novel antidepressants, including some psychedelics. Specifically, GLPG3970 blocks stress-induced increases in SIK2 expression and prevents the cytoplasmic translocation of CRTC1, thereby restoring CREB-mediated transcription and brain-derived neurotrophic factor (BDNF) signaling. Restoration of BDNF signaling is associated with increased neurogenesis in the hippocampus, a process believed to underlie the behavioral improvements observed in the study.

Notably, the study used adeno-associated virus (AAV)-mediated gene transfer to demonstrate that overexpression of SIK2 or silencing of CRTC1, CREB, or BDNF in the hippocampus abolished the antidepressant-like effects of GLPG3970. This provides strong evidence for the necessity of the SIK2-CRTC1-CREB-BDNF axis in mediating the observed behavioral outcomes.

Context: Overlap with Psychedelic Mechanisms and Research Implications

The mechanistic overlap between GLPG3970’s action and pathways implicated in psychedelic-induced neuroplasticity is of particular interest. Both GLPG3970 and several psychedelics, such as psilocybin, upregulate BDNF signaling and promote synaptic plasticity in the hippocampus. This convergence suggests potential for cross-fertilization in drug development, including the design of combination therapies or the use of SIK2/3 inhibitors as adjuncts to psychedelic-assisted interventions.

For neuroscience researchers, the study highlights the value of targeting intracellular signaling cascades that regulate neurotrophic factors. For clinical trial designers, the findings suggest new endpoints—such as hippocampal neurogenesis or BDNF levels—that could be measured in future early-phase studies of GLPG3970 or related compounds.

Importantly, GLPG3970 is not a psychedelic and does not appear to induce altered states of consciousness in animal models, which may make it more palatable to regulators and patients wary of psychoactive effects. This distinction could shape the competitive landscape for next-generation antidepressants, especially as the field moves beyond monoaminergic targets.

Risks, Unknowns, and Translational Challenges

Despite the promising preclinical results, several risks and unknowns remain. The study was conducted exclusively in male mice, and it is unclear whether similar effects would be observed in females or in humans. The chronic stress models used, while validated, do not fully recapitulate the complexity of human depression, and many compounds with robust mouse data have failed in clinical trials due to species differences or unforeseen toxicity.

Another challenge is the specificity of GLPG3970 for SIK2/3 and the potential for off-target effects, especially given the broad role of kinases in cellular signaling. Long-term safety data are lacking, and the impact of chronic SIK2/3 inhibition on other physiological systems has not been established. Furthermore, while the SIK2-CRTC1-CREB-BDNF pathway is a promising target, its modulation could have unintended consequences, such as altered stress responses or cognitive effects, which require careful evaluation in future studies.

Forward Outlook: Next Steps and Industry Implications

The preclinical success of GLPG3970 positions it as a candidate for further development, but translation to human trials will require rigorous toxicology, pharmacokinetic, and efficacy studies. If future research confirms its safety and efficacy, GLPG3970 could enter Phase 1 clinical trials as early as 2027, subject to regulatory approval and successful investigational new drug (IND) application filings.

For industry stakeholders, the study underscores the importance of mechanistic diversity in antidepressant pipelines. Companies developing psychedelics or other neuroplasticity-promoting agents may consider SIK2/3 inhibitors as potential competitors or combination partners. The non-psychedelic profile of GLPG3970 could also appeal to patient populations or jurisdictions where acceptance of classic psychedelics remains limited.

One non-obvious implication is that advances in SIK2/3 inhibition may inform biomarker development for both psychedelic and non-psychedelic antidepressants, enabling more precise patient stratification and outcome measurement in future trials.

How we research: This article was written and reviewed by Dr. Alex Kim, PhD (Neuroscience), on 2026-10-02. Primary data were sourced directly from the original OpenAlex publication and supporting regulatory and scientific literature.